Disease · EFO_0803536
Trials877
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 29 more are not shown, since the checks do not confirm them.
1 to 20 of 877
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01585298 | STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START) | Phase 4 | 6,998 | 2019-09-23 | Multiple Sclerosis | FINGOLIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT01201356 | Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis | Phase 3 | 4,125 | 2019-11-07 | Relapsing Forms of Multiple Sclerosis | FINGOLIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT03193866 | COMparison Between All immunoTherapies for Multiple Sclerosis. | 3,526 | 2025-04-20 | Relapsing-remitting Multiple Sclerosis | RITUXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT02576717 | A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | Phase 3 | 2,494 | 2024-01-30 | Multiple Sclerosis | OZANIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT01707992 | The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) | Phase 3 | 2,199 | 2019-03-13 | Multiple Sclerosis | LAQUINIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | Phase 3 | 1,841 | 2016-07-11 | Relapsing-Remitting Multiple Sclerosis | DACLIZUMAB, INTERFERON BETA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | Phase 3 | 1,736 | 2020-12-31 | Relapsing-Remitting Multiple Sclerosis | DIMETHYL FUMARATE | Its record names the disease | ClinicalTrials.gov |
| NCT01665144 | Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) | Phase 3 | 1,651 | 2018-10-31 | Secondary Progressive Multiple Sclerosis | SIPONIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00906399 | Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis | Phase 3 | 1,516 | 2014-09-19 | Relapsing Multiple Sclerosis | PEGINTERFERON BETA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | Phase 3 | 1,501 | 2019-12-04 | Relapsing-Remitting Multiple Sclerosis, Multiple Sclerosis | DACLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00459667 | BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose | Phase 3 | 1,420 | 2009-08-17 | Multiple Sclerosis, Relapsing-Remitting | INTERFERON BETA-1B | Its record names the disease | ClinicalTrials.gov |
| NCT00451451 | Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis | Phase 3 | 1,417 | 2014-06-02 | Relapsing-Remitting Multiple Sclerosis | DIMETHYL FUMARATE, GLATIRAMER ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT01067521 | A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo | Phase 3 | 1,404 | 2018-10-09 | Relapsing Remitting Multiple Sclerosis | GLATIRAMER ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT02294058 | Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) | Phase 3 | 1,346 | 2020-11-25 | Multiple Sclerosis | OZANIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00605215 | BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®) | Phase 3 | 1,331 | 2022-04-21 | Multiple Sclerosis | INTERFERON BETA-1A, LAQUINIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00213135 | A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | 1,326 | 2013-12-02 | Multiple Sclerosis, Relapsing-Remitting | CLADRIBINE | Its record names the disease | ClinicalTrials.gov |
| NCT02047734 | Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis | Phase 3 | 1,320 | 2021-02-11 | Relapsing Multiple Sclerosis | INTERFERON BETA-1A, OZANIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00340834 | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase | Phase 3 | 1,292 | 2011-05-16 | Multiple Sclerosis | FINGOLIMOD, INTERFERON BETA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT00289978 | Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis | Phase 3 | 1,272 | 2011-03-16 | Relapsing-remitting Multiple Sclerosis | FINGOLIMOD | Its record names the disease | ClinicalTrials.gov |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | Phase 3 | 1,234 | 2014-06-02 | Relapsing-Remitting Multiple Sclerosis | DIMETHYL FUMARATE | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0803536/trials